FCRLA/FCRLM1 Antibody [Alexa Fluor® 488]

• Applications: WB
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor 488

FCRLA/FCRLM1 Antibody [Alexa Fluor® 488] Summary

• Immunogen: E. coli-derived recombinant mouse FCRLA
  Lys221-Lys352 (Ile321Met)
  Accession # Q920A9
• Specificity: Detects mouse FCRLA in direct ELISAs and Western blots. In direct ELISA, less than 5% cross-reactivity with recombinant human FCRLA is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Purity Statement: Antigen Affinity-purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

FCRLA (Fc Receptor-Like A; also known as FcRX and Fc receptor Homolog Expressed in B cells) is a 44 kDa intracellular member of the Fc gamma RI class, FcR family, Immunoglobulin Superfamily of molecules. It is associated with B lineage cells, and has been identified in virtually all splenic B cells, peritoneal B1b and B2 B cells, and immature through mature bone marrow B cells. Not all cells show equal expression patterns. In the spleen, weak FCRLA expression occurs in naïve follicular and marginal zone B cells, and increases with activation state. FcRLA is suggested to act as an ER chaperone during antibody maturation, and is known to bind to IgM, IgA, and IgG prior to their secretion. Mouse FCRLA is synthesized as a 34 kDa, 322 amino acid (aa) precursor that contains a 30 aa signal sequence, two C2‑type Ig‑like domains (aa 80-169 and 182-26), and a C-terminal poly-Proline region (aa 289-294). Although there is no traditional ER retention signal, a viable substitute is assumed to exist at the N-terminus of the mature molecule. FCRLA is believed to exist naturally as a monomer; however, disulfide-linkage can occur during experimental manipulation. While four potential isoform variants are reported, it is unclear if any are actually expressed. One shows an Ala insertion after Ala28, a second shows an AlaIle substitution for aa 20-22, a third contains that previous AlaIle substitution coupled to a deletion of aa 90-115, while a fourth utilizes an alternative start site at Met62. Over aa 221-352, mouse FCRLA shares 68% and 55% aa sequence identity with rat and human FCRLA, respectively.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.